<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01769105</url>
  </required_header>
  <id_info>
    <org_study_id>HHUAU052012</org_study_id>
    <nct_id>NCT01769105</nct_id>
  </id_info>
  <brief_title>Comparison of Lipiflow®-Treatment and a Standard Lid Hygiene Regime</brief_title>
  <official_title>Prospective, Randomized, Controlled Comparison of an Automated Thermal Pulsation Treatment (Lipiflow ®) and a Standard Lid Hygiene Regime</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, beneficial effects on Meibomian gland dysfunction (MGD) of a single automated
      thermal pulsation with the Lipiflow® system have been reported in several case reports. In
      one study this treatment was compared with hyperthermia (iheat®) for 4 weeks. However,
      treatment recommendations for lid hygiene according to the MGD-report consist of hyperthermia
      followed by lid massage and lid margin cleansing over several months. To the best of the
      investigators knowledge this is the first randomized prospective study to compare automated
      thermal pulsation treatment with the new Lipiflow ® system with a standard lid hygiene
      regime.

      The investigators suggest that a single treatment with Lipiflow® is superior to a lid hygiene
      regime.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Once a patient has been identified as a possible candidate for the study, he/she is first
      informed verbally and in writing about the study. After signing the consent form he/she will
      be randomized to either the Lipiflow® treatment (Lipiflow® group) or alternatively be given
      an instruction sheet and a verbal explanation for lid warming and massage (lid hygiene
      group). After 3 month a cross-over of the lid hygiene group to the Lipiflow® group is
      conducted.

      A full examination is performed before and 4 weeks and 3 months after therapy. All tests are
      performed by a physician or trained graduate students of the Department of Ophthalmology,
      Heinrich-Heine University. The examiner is blinded, i.e. he does not know which treatment the
      patient will receive or receiving.

      Treatment Lipiflow®:

      The automated thermal pulsation with Lipiflow® provides is a low risk therapy. After local
      anesthesia the applicators are inserted. These look like a kind of goggles and consist of two
      parts which embrace the eyelids from the front and from behind. Through the rear part heat is
      applied to a maximum of 42.5° C. By isolating the heat remains on the eyelid limited. Through
      the front part the gland a massage is performed. The treatment takes 12 minutes per eye and
      can be done depending on the patient's wishes simultaneously or one eye after the other. The
      therapy is approved by the FDA as a medical technical innovation and has also been approved
      by ISO and CE Mark certification for use in Europe. Irritation or minor trauma of the eyelids
      and the conjunctiva and cornea, as well as a violation of the eyelids and the conjunctiva and
      cornea are theoretically possible, but extremely unlikely. Permanent damages to the eyes have
      not been reported in the literature.

      In the unlikely event, that complications occur during treatment, requiring an additional
      treatment, this is performed in the department of ophthalmology of the Heinrich-Heine
      University Duesseldorf.

      Test parameters:

      At any time of investigation, the following parameters are evaluated:

      Lipiview®, Tear Lab®, Schirmer test, break-up time, corneal and conjunctival fluorescein
      staining, Meibomian gland evaluation (MGE), examination of the eyelids, Meibography, OSDI
      score, SPEED score

      All test parameters are established procedures and have in common a very low risk of harm to
      the patient. In detail:

      The Lipiview® is a device that quantifies the thickness of the lipid layer of the tear film
      using interferometry. For this the patient looks into a kind of camera while recordings of
      his tear film are made, which are then analyzed by a computer.

      Tear Lab® is a method for measuring tear film osmolarity. A pen-like instrument (the
      osmometer) is held on the tear meniscus and collects 100 nl tears within fractions of a
      second in the unit. There is no need for local anaesthesia. By electrical impedance
      measurement, then the tear film osmolarity is measured. The examiner can then read the values
      digitally.

      The Schirmer test consists of a strip of filter paper that is placed in the conjunctival sac
      of the patient for five minutes. The filter paper absorbs the tear fluid and the stained by
      the tear fluid line serves as a measure of tear secretion.

      Tear break-up time is the time between a blink and the tear film shows signs of breaking up.
      In this study this is measured non-invasive with the Oculus-Keratograph 5 M®. The patient
      looks into a kind of camera while recordings of his tear film are made which are then
      analyzed by a computer.

      Vital corneal and conjunctival epithelium cannot be stained by fluorescein. The dye adheres
      to nonviable cells. The degree of staining, can be judged by the investigator by slit-lamp
      examination.

      For evaluation of the secreting meibomian glands a specialized device (Meibomian gland
      evaluator) is used, that provides a defined pressure to the lid. The examiner observes the
      ducts of the Meibomian glands and assesses how many glands are yielding secretion.

      Examination of the eyelids is done using a slit lamp to assess a thickening or a significant
      vascularisation the lid margin.

      To perform meibography the lids are illuminated by infrared light. Functional acini of the
      glands become clearly visible and can be differentiated from atrophic acini. The number of
      atrophic meibomian glands can be counted by a score.

      OSDI (Ocular-Surface-Disease-Index) and SPEED (Standard Pattern Evaluation of Eye Dryness)
      are questionnaires to quantify the symptoms of dry eye.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Dry Eye Symptoms</measure>
    <time_frame>after 3 month compared to baseline value</time_frame>
    <description>The symptoms of dry eyes are measured in our study with the OSDI and the SPEED questionaire. Primary outcome measure (OSDI)
Patients completed two symptom questionnaires: OSDI (Ocular Surface Disease Index) and SPEED (Standard Patient Evaluation of Eye dryness).
OSDI scores range from 0 (no symptoms) to 100 (severe symptoms). SPEED scores range from 0 (no symptoms) to 28 (severe symptoms). So a reduction of the OSDI or SPEED score indicates an improvement of subjective dry eye symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Break-up-time</measure>
    <time_frame>after 3 month compared to baseline value</time_frame>
    <description>break-up-time is measured non-invasive with the Oculus Keratograph 5 M;
The break-up-time is measured in seconds. A low break-up-time suggests a lower lipid layer thickness. A higher break-up-time can be regarded as an improvement of ocular surface lubrication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tear Film Osmolarity</measure>
    <time_frame>after 3 month compared to baseline value</time_frame>
    <description>osmolarity is measured with the tear-lab;
The osmolarity is measured in mOsm/l. A higher osmolarity can be regarded as an objective sign of dry eye disease.
A lower osmolarity after therapy can be regarded as an improvement of ocular surface disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lipid Layer Thickness</measure>
    <time_frame>after 3 month compared to baseline value</time_frame>
    <description>lipid layer thickness (LLT) is measured with the Lipiview-interferometer;
High values of LLT indicate a better lubrication of the ocular surface, so an increase in LLT can be regarded in an improvement of ocular surface.
LLT is measured in Interferometric color units (ICUs) whereas 1 ICU reflects about 1 nm lipid layer thickness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Expressible Meibomian Glands</measure>
    <time_frame>after 3 month compared to baseline value</time_frame>
    <description>expressible Meibomian glands are measured with the Meibomian gland evaluator; A higher number of expressible Meibomian glands indicate a lower likelihood Meibomian Gland dysfunction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>Standard Lid Hygiene Regime</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive detailed verbal and written instruction to perform lid hygiene twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lipiflow</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive a singe Lipiflow-treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lipiflow</intervention_name>
    <description>Patients receive a single Lipiflow-treatment</description>
    <arm_group_label>Lipiflow</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lid hygiene regime</intervention_name>
    <description>Patients receive verbal and written instruction to perform lid hygiene twice daily</description>
    <arm_group_label>Standard Lid Hygiene Regime</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with meibomian gland dysfunction requiring treatment (defined below),

          -  who have given their written consent to the study.

          -  Meibomian gland dysfunction requiring treatment is classified by us as:

          -  Speed score&gt; 7, Lipiview &lt;61 nm, MGE &lt;5 of 15 open glands

        Exclusion Criteria:

          -  Excluded are patients who, due to other diseases would not be able to fulfill the
             follow-up appointments or give an informed consent to the study

          -  Systemic medication with tetracyclin derivatives, antihistamines, isotretinoin, or
             nutritional supplements for MGD that started &lt;3 months before baseline examination

          -  Topical cyclosporine-A or steroids that started &lt;1 month before baseline examination

          -  Ocular surgery or trauma &lt;3 months before baseline examination

          -  Any eyelid abnormalities

          -  Systemic diseases resulting in dry eye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerd Geerling, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Deparmtent of ophthalmology, Heinrich-Heine-University, Duesseldorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Deparment of ophthalmology, Heinrich-Heine-University</name>
      <address>
        <city>Duesseldorf</city>
        <zip>D-40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Finis D, Hayajneh J, König C, Borrelli M, Schrader S, Geerling G. Evaluation of an automated thermodynamic treatment (LipiFlow®) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial. Ocul Surf. 2014 Apr;12(2):146-54. doi: 10.1016/j.jtos.2013.12.001. Epub 2014 Jan 22.</citation>
    <PMID>24725326</PMID>
  </results_reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2013</study_first_submitted>
  <study_first_submitted_qc>January 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2013</study_first_posted>
  <results_first_submitted>September 1, 2014</results_first_submitted>
  <results_first_submitted_qc>October 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 7, 2014</results_first_posted>
  <last_update_submitted>October 6, 2014</last_update_submitted>
  <last_update_submitted_qc>October 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heinrich-Heine University, Duesseldorf</investigator_affiliation>
    <investigator_full_name>David Finis, MD</investigator_full_name>
    <investigator_title>Principal investigator, department of ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Meibomian Gland Dysfunction</keyword>
  <keyword>Lipiflow</keyword>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Five patients had been enrolled in the study, but withdrew their participation after baseline examination for personal reasons. They did not receive any treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard Lid Hygiene Regime First, Then Lipiflow</title>
          <description>Patients receive detailed verbal and written instruction to perform lid hygiene twice daily, then Lipiflow
Lid hygiene regime: Patients receive verbal and written instruction to perform lid hygiene twice daily and after 3 month a single Lipiflow treatment</description>
        </group>
        <group group_id="P2">
          <title>Lipiflow</title>
          <description>Patients receive a singe Lipiflow-treatment
Lipiflow: Patients receive a single Lipiflow-treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Cross-over</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0">Cross-over was only intended for the Lid margin hygiene group</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0">Was not intended by the study protocol</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Lid Hygiene Regime First, Then Lipiflow</title>
          <description>Patients receive detailed verbal and written instruction to perform lid hygiene twice daily, then Lipiflow
Lid hygiene regime: Patients receive verbal and written instruction to perform lid hygiene twice daily, then a single Lipiflow-treatment</description>
        </group>
        <group group_id="B2">
          <title>Lipiflow</title>
          <description>Patients receive a singe Lipiflow-treatment
Lipiflow: Patients receive a single Lipiflow-treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="19"/>
                    <measurement group_id="B2" value="45" spread="23"/>
                    <measurement group_id="B3" value="47" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of Dry Eye Symptoms</title>
        <description>The symptoms of dry eyes are measured in our study with the OSDI and the SPEED questionaire. Primary outcome measure (OSDI)
Patients completed two symptom questionnaires: OSDI (Ocular Surface Disease Index) and SPEED (Standard Patient Evaluation of Eye dryness).
OSDI scores range from 0 (no symptoms) to 100 (severe symptoms). SPEED scores range from 0 (no symptoms) to 28 (severe symptoms). So a reduction of the OSDI or SPEED score indicates an improvement of subjective dry eye symptoms.</description>
        <time_frame>after 3 month compared to baseline value</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Lid Hygiene Regime</title>
            <description>Patients receive detailed verbal and written instruction to perform lid hygiene twice daily
Lid hygiene regime: Patients receive verbal and written instruction to perform lid hygiene twice daily</description>
          </group>
          <group group_id="O2">
            <title>Lipiflow</title>
            <description>Patients receive a singe Lipiflow-treatment
Lipiflow: Patients receive a single Lipiflow-treatment</description>
          </group>
          <group group_id="O3">
            <title>Cross-over Lipiflow</title>
            <description>patients received a single Lipiflow treatment after performing lid hygiene for 3 month</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Dry Eye Symptoms</title>
          <description>The symptoms of dry eyes are measured in our study with the OSDI and the SPEED questionaire. Primary outcome measure (OSDI)
Patients completed two symptom questionnaires: OSDI (Ocular Surface Disease Index) and SPEED (Standard Patient Evaluation of Eye dryness).
OSDI scores range from 0 (no symptoms) to 100 (severe symptoms). SPEED scores range from 0 (no symptoms) to 28 (severe symptoms). So a reduction of the OSDI or SPEED score indicates an improvement of subjective dry eye symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OSDI Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.1" spread="16.7"/>
                    <measurement group_id="O2" value="46.2" spread="14.8"/>
                    <measurement group_id="O3" value="39.7" spread="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPEED Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" spread="6.6"/>
                    <measurement group_id="O2" value="16.8" spread="5.6"/>
                    <measurement group_id="O3" value="14.7" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OSDI 3 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" spread="23.4"/>
                    <measurement group_id="O2" value="34.6" spread="19.6"/>
                    <measurement group_id="O3" value="32.8" spread="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPEED 3 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" spread="7.1"/>
                    <measurement group_id="O2" value="14.5" spread="7.2"/>
                    <measurement group_id="O3" value="12.6" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Break-up-time</title>
        <description>break-up-time is measured non-invasive with the Oculus Keratograph 5 M;
The break-up-time is measured in seconds. A low break-up-time suggests a lower lipid layer thickness. A higher break-up-time can be regarded as an improvement of ocular surface lubrication.</description>
        <time_frame>after 3 month compared to baseline value</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Lid Hygiene Regime</title>
            <description>Patients receive detailed verbal and written instruction to perform lid hygiene twice daily
Lid hygiene regime: Patients receive verbal and written instruction to perform lid hygiene twice daily</description>
          </group>
          <group group_id="O2">
            <title>Lipiflow</title>
            <description>Patients receive a singe Lipiflow-treatment
Lipiflow: Patients receive a single Lipiflow-treatment</description>
          </group>
          <group group_id="O3">
            <title>Cross-over Lipiflow</title>
            <description>Patients receive Lipiflow after performing Lid hygiene for 3 month</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Break-up-time</title>
          <description>break-up-time is measured non-invasive with the Oculus Keratograph 5 M;
The break-up-time is measured in seconds. A low break-up-time suggests a lower lipid layer thickness. A higher break-up-time can be regarded as an improvement of ocular surface lubrication.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="6.1"/>
                    <measurement group_id="O2" value="7.9" spread="8.5"/>
                    <measurement group_id="O3" value="6.7" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 3 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="6.1"/>
                    <measurement group_id="O2" value="9.9" spread="7.0"/>
                    <measurement group_id="O3" value="7.3" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Tear Film Osmolarity</title>
        <description>osmolarity is measured with the tear-lab;
The osmolarity is measured in mOsm/l. A higher osmolarity can be regarded as an objective sign of dry eye disease.
A lower osmolarity after therapy can be regarded as an improvement of ocular surface disease.</description>
        <time_frame>after 3 month compared to baseline value</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Lid Hygiene Regime</title>
            <description>Patients receive detailed verbal and written instruction to perform lid hygiene twice daily
Lid hygiene regime: Patients receive verbal and written instruction to perform lid hygiene twice daily</description>
          </group>
          <group group_id="O2">
            <title>Lipiflow</title>
            <description>Patients receive a singe Lipiflow-treatment
Lipiflow: Patients receive a single Lipiflow-treatment</description>
          </group>
          <group group_id="O3">
            <title>Cross-over Lipiflow</title>
            <description>Patients receive Lipiflow after performing Lid hygiene for 3 month</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tear Film Osmolarity</title>
          <description>osmolarity is measured with the tear-lab;
The osmolarity is measured in mOsm/l. A higher osmolarity can be regarded as an objective sign of dry eye disease.
A lower osmolarity after therapy can be regarded as an improvement of ocular surface disease.</description>
          <units>mOsm/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="296.7" spread="10.2"/>
                    <measurement group_id="O2" value="301.5" spread="11.4"/>
                    <measurement group_id="O3" value="305.0" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 3 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303.7" spread="8.1"/>
                    <measurement group_id="O2" value="307.1" spread="14.0"/>
                    <measurement group_id="O3" value="310.0" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lipid Layer Thickness</title>
        <description>lipid layer thickness (LLT) is measured with the Lipiview-interferometer;
High values of LLT indicate a better lubrication of the ocular surface, so an increase in LLT can be regarded in an improvement of ocular surface.
LLT is measured in Interferometric color units (ICUs) whereas 1 ICU reflects about 1 nm lipid layer thickness.</description>
        <time_frame>after 3 month compared to baseline value</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Lid Hygiene Regime</title>
            <description>Patients receive detailed verbal and written instruction to perform lid hygiene twice daily
Lid hygiene regime: Patients receive verbal and written instruction to perform lid hygiene twice daily</description>
          </group>
          <group group_id="O2">
            <title>Lipiflow</title>
            <description>Patients receive a singe Lipiflow-treatment
Lipiflow: Patients receive a single Lipiflow-treatment</description>
          </group>
          <group group_id="O3">
            <title>Cross-over Lipiflow</title>
            <description>Patients receive Lipiflow after performing Lid hygiene for 3 month</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lipid Layer Thickness</title>
          <description>lipid layer thickness (LLT) is measured with the Lipiview-interferometer;
High values of LLT indicate a better lubrication of the ocular surface, so an increase in LLT can be regarded in an improvement of ocular surface.
LLT is measured in Interferometric color units (ICUs) whereas 1 ICU reflects about 1 nm lipid layer thickness.</description>
          <units>nm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1" spread="7.9"/>
                    <measurement group_id="O2" value="43.4" spread="9.9"/>
                    <measurement group_id="O3" value="45.8" spread="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 3 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4" spread="20.8"/>
                    <measurement group_id="O2" value="47.4" spread="16.7"/>
                    <measurement group_id="O3" value="59.2" spread="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Expressible Meibomian Glands</title>
        <description>expressible Meibomian glands are measured with the Meibomian gland evaluator; A higher number of expressible Meibomian glands indicate a lower likelihood Meibomian Gland dysfunction.</description>
        <time_frame>after 3 month compared to baseline value</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Lid Hygiene Regime</title>
            <description>Patients receive detailed verbal and written instruction to perform lid hygiene twice daily
Lid hygiene regime: Patients receive verbal and written instruction to perform lid hygiene twice daily</description>
          </group>
          <group group_id="O2">
            <title>Lipiflow</title>
            <description>Patients receive a singe Lipiflow-treatment
Lipiflow: Patients receive a single Lipiflow-treatment</description>
          </group>
          <group group_id="O3">
            <title>Cross-over Lipiflow</title>
            <description>Patients receive Lipiflow after performing Lid hygiene for 3 month</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Expressible Meibomian Glands</title>
          <description>expressible Meibomian glands are measured with the Meibomian gland evaluator; A higher number of expressible Meibomian glands indicate a lower likelihood Meibomian Gland dysfunction.</description>
          <units>number of expressible glands</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.3"/>
                    <measurement group_id="O2" value="2.5" spread="1.4"/>
                    <measurement group_id="O3" value="4.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 3 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="3.8"/>
                    <measurement group_id="O2" value="5.5" spread="3.6"/>
                    <measurement group_id="O3" value="5.8" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard Lid Hygiene Regime First, Then Lipiflow</title>
          <description>Patients receive detailed verbal and written instruction to perform lid hygiene twice daily first and then Lipiflow
Lid hygiene regime: Patients receive verbal and written instruction to perform lid hygiene twice daily and after 3 month a single Lipiflow-treatment</description>
        </group>
        <group group_id="E2">
          <title>Lipiflow</title>
          <description>Patients receive a singe Lipiflow-treatment
Lipiflow: Patients receive a single Lipiflow-treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>For further information please have a look at Finis et al: Evaluation of an automated thermodynamic treatment (LipiFlow®) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial.Ocul Surf. 2014 Apr;12(2):146-54.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. David Finis</name_or_title>
      <organization>Department of ophthalmology, University of Duesseldorf</organization>
      <phone>+49 211 8117320</phone>
      <email>David.Finis@med.uni-duesseldorf.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

